When someone has severe asthma that doesn't respond well to traditional inhalers and corticosteroids, biological treatments (often called "biologics") represent a different approach entirely. Rather than using medications that simply open airways or reduce general inflammation throughout the lungs, biologics target specific parts of the immune system that drive asthma in certain individuals.
Learn About Paying Your FGUA Bill Online →
Standard asthma medications like albuterol and fluticasone work broadly—they relax muscles around airways or calm inflammation everywhere in the respiratory system. This works well for many people, but about 5-10% of asthma patients have severe disease that persists despite using these standard treatments correctly. For these individuals, the problem often involves specific immune pathways that standard drugs don't address.
Biological treatments are manufactured proteins designed to block particular inflammatory molecules or immune cells. Think of them as precision tools rather than general-purpose cleaners. If your severe asthma involves too many eosinophils (a type of white blood cell), a biologic might block the signals that recruit these cells into your airways. If your asthma is driven by IgE antibodies (immune proteins that cause allergic reactions), a different biologic can bind to those antibodies before they trigger inflammation.
These medications work because they interrupt the specific biological pathway driving your asthma. Someone with allergic asthma, eosinophilic asthma, or asthma tied to specific immune patterns may see significant improvement when the right biologic is matched to their condition. Studies show that patients using appropriate biologics can reduce hospitalizations by 50% or more, cut oral steroid use substantially, and experience fewer asthma attacks overall.
Key takeaway: Biologics aren't replacements for rescue inhalers or preventive steroids—they're additional tools designed to target the immune system mechanisms that keep severe asthma active in certain patients.
Several different biological treatments for asthma are currently available, each targeting different immune pathways. Understanding which ones exist helps you recognize what your doctor might discuss with you.
Free Guide to Pay by Plate Illinois Billing →
Anti-IgE medications (Omalizumab/Xolair): This was the first biologic approved for asthma and remains one of the most commonly prescribed. It binds to IgE antibodies before they can attach to mast cells and trigger allergic reactions. This drug works best for people whose asthma is clearly linked to allergies—those with documented allergies who also have moderate-to-severe persistent asthma. Patients typically receive injections under the skin every 2-4 weeks. Studies show about 60% of appropriate patients experience meaningful improvements.
Anti-IL-5 medications (Mepolizumab/Nucala, Reslizumab/Cinqair): These block interleukin-5 (IL-5), a chemical messenger that recruits eosinophils into airways. They're designed for eosinophilic asthma—cases where blood tests show high eosinophil counts. Patients typically need injections or infusions every 4 weeks. Clinical trials show these can reduce asthma attacks by 40-50% in eosinophil-driven asthma.
Anti-IL-4 receptor medication (Dupilumab/Dupixent): This blocks the IL-4 receptor, which dampens multiple type-2 immune pathways simultaneously. It works for both allergic and eosinophilic asthma patterns. Some patients use it as an injection every 2 weeks after an initial loading dose. It's also approved for eczema and nasal polyps, so it may help if you have multiple conditions.
TSLP antagonist (Tezepelumab/Tezspire): This relatively newer option blocks thymic stromal lymphopoietin (TSLP), an upstream trigger in type-2 inflammation. It's being studied across different asthma types, including those that don't fit neatly into allergic or eosinophilic categories.
Key takeaway: Different biologics target different immune pathways, which is why doctors need specific test results—like allergy panels or eosinophil counts—to determine which one might work for your situation.
Biological treatments for severe asthma aren't prescribed randomly—they're reserved for people with specific patterns of severe disease who haven't achieved control with standard treatments. Understanding the typical patient profile helps clarify whether this information might relate to your situation or someone you know.
Free Guide to Mold Removal Methods for Walls →
The most common scenario involves someone who has been diagnosed with asthma, is using inhaled corticosteroids consistently and correctly, but still experiences frequent symptoms or attacks. "Frequent" typically means 2 or more asthma attacks per week, or nighttime awakenings from asthma more than once weekly, or significant activity limitation from asthma symptoms. These people have tried optimizing their standard medications—using them correctly, addressing triggers, checking inhaler technique—and still aren't getting the control they need.
Another pattern involves patients who require frequent oral corticosteroid courses. Someone might need oral prednisone or methylprednisolone multiple times yearly to control asthma flares. While these steroids help in the short term, repeated courses carry risks including weakened bones, increased infection risk, weight gain, and mood changes. If someone needs oral steroids more than twice yearly, doctors often consider whether a biologic might reduce that dependence.
A third group includes people with very severe asthma that's clearly allergic or eosinophilic in nature. They might have documented high IgE levels, positive skin tests to multiple allergens, or blood eosinophil counts above 300-400 cells per microliter. These measurable patterns suggest their immune system is driving asthma in a specific way that a matched biologic might address.
Age matters somewhat—most biologics are approved for people 12 and older, though a few have approval for younger children. Cost and insurance coverage vary considerably, which affects who actually receives these treatments despite medical suitability. Approximately 1-3% of asthma patients meet criteria for biological treatment, though awareness and access differ across regions.
Key takeaway: Biological treatment consideration typically follows a pattern: diagnosed severe asthma that persists despite proper standard therapy, often with measurable immune markers that match available biologics.
Prescribing a biological treatment for severe asthma isn't a guessing game—doctors use specific test results and clinical information to match patients with the biologic most likely to help them. This matching process is crucial because the right drug for one person may not help another, even if both have severe asthma.
How to Delete Your Fitbit Account Guide →
Blood eosinophil counts are among the most important measurements. A simple blood test shows how many eosinophils (a type of white blood cell) are circulating. Normal levels are below 300 cells per microliter. Counts of 300-500 might suggest eosinophilic asthma and could point toward anti-IL-5 medications. Counts above 400-500 make anti-IL-5 biologics more likely to work. Different biologics have different eosinophil thresholds—some work better with higher counts, others can help even with moderate counts.
Allergy testing helps determine if someone's asthma is allergically driven. Doctors might order skin prick tests (where tiny amounts of allergen extract are applied to skin) or radioallergosorbent tests (RAST blood tests) to identify specific allergens someone reacts to. Someone highly allergic to dust mites, pollen, pet dander, or mold who also has asthma might benefit from anti-IgE treatment like omalizumab.
IgE levels measure the total amount of IgE antibodies in blood. Very high IgE levels (above 700 international units per milliliter) might suggest anti-IgE therapy could help. However, moderate IgE levels
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.